Niagen Bioscience, Inc.
NAGE
$9.88
-$0.16-1.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,411.32% | 499.80% | 273.15% | 122.95% | 79.19% |
| Total Depreciation and Amortization | -10.37% | -23.97% | -32.73% | -34.97% | -30.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -132.49% | -136.94% | -112.47% | -27.45% | -16.92% |
| Change in Net Operating Assets | 204.64% | 406.51% | -31.30% | -161.01% | -647.99% |
| Cash from Operations | 1,871.28% | 326.34% | 70.14% | -32.00% | -46.31% |
| Capital Expenditure | -177.00% | -57.14% | -10.14% | 61.54% | 69.23% |
| Sale of Property, Plant, and Equipment | -- | 300.00% | 300.00% | 300.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -157.00% | -44.09% | 0.00% | 67.69% | 68.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -33.33% | 35.29% | 26.67% | 50.00% | 55.00% |
| Issuance of Common Stock | 1,856.52% | -- | -- | -78.82% | -92.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 38.37% | 45.35% | 30.67% | -38.71% | -11.69% |
| Cash from Financing | 2,213.12% | 8,340.78% | 6,065.56% | -79.84% | -93.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,103.45% | 534.06% | 151.82% | -58.37% | -84.15% |